Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
5.49
+0.04 (0.73%)
At close: Apr 28, 2026, 4:00 PM EDT
5.49
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Company Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States.
Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Atossa Therapeutics, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Nov 8, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Steven Quay |
Contact Details
Address: 448 NW Market Street, Suite 500 Seattle, Washington 98107 United States | |
| Phone | 206 588 0256 |
| Website | atossatherapeutics.com |
Stock Details
| Ticker Symbol | ATOS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001488039 |
| CUSIP Number | 04962H704 |
| ISIN Number | US04962H7044 |
| Employer ID | 26-4753208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Mark J. Daniel CPA | Chief Financial Officer |
| Janet Rose Rea MSPH, RAC | Senior Vice President of Research and Development |
| Delly Behen P.H.R. | Senior Vice President of Business Operations |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2026 | 8-K | Current Report |
| Mar 30, 2026 | ARS | Filing |
| Mar 30, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 424B5 | Filing |
| Feb 20, 2026 | 424B3 | Prospectus |
| Feb 17, 2026 | 8-K | Current Report |